ARPA-H launched BioStabilization Systems (BoSS) funding to address the cold-chain barrier for cell-based biologics. ARPA-H committed up to $87 million across the program’s four-year timeline, with the current round supporting Phase I, including a Reversible Ambient Temperature (RAB) team led administratively by Draper and technically by Likarda. The RAB team plans AI-assisted design of experiments to optimize formulation and quiescence induction parameters, using hydrogel-based stabilization and freeze-assisted droplet drying to enable stable storage and on-demand recovery. The focus is on making shelf-life stability and scalable processing achievable without refrigeration. For biotech developers, the BoSS program is a signal that manufacturing and distribution constraints are becoming first-order innovation targets, not afterthoughts. If successful, room-temperature approaches could expand where CAR-T, other cell therapies, and complex biologics can be delivered and could shorten the time-to-treatment in real-world care settings.